The multicenter ACCESS trial reported data suggesting that blood cancer patients without closely matched stem cell donors may still benefit from carefully selected younger donors with substantial genetic mismatches. The strategy pairs transplantation with post-transplant cyclophosphamide, a regimen designed to control graft-versus-host disease risk while enabling engraftment. The findings support expanding donor selection beyond the most stringent match categories, potentially increasing access for patients who would otherwise face long delays or limited donor availability. The study emphasizes selection criteria and pairing with the post-transplant strategy rather than mismatches alone. For transplant centers, the reported approach could influence how donor search and conditioning plans are built in real-world pathways, especially as waiting times and donor pool constraints remain operational constraints in hematology.